214 related articles for article (PubMed ID: 34900670)
1. Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment.
Chen P; Wang H; Zhao L; Guo H; Zhang L; Zhang W; Sun C; Zhao S; Li W; Zhu J; Yu J; Wu C; He Y
Front Oncol; 2021; 11():713853. PubMed ID: 34900670
[TBL] [Abstract][Full Text] [Related]
2. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.
He Y; Zhang X; Jia K; Dziadziuszko R; Zhao S; Deng J; Wang H; Hirsch FR; Zhou C
Transl Lung Cancer Res; 2019 Aug; 8(4):352-366. PubMed ID: 31555511
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma.
Chen X; Ma H; Mo S; Zhang Y; Lu Z; Yu S; Chen J
Front Immunol; 2022; 13():942154. PubMed ID: 35936015
[TBL] [Abstract][Full Text] [Related]
4. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T
Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203
[TBL] [Abstract][Full Text] [Related]
5. High Serum OX40 and OX40 Ligand (OX40L) Levels Correlate with Reduced Survival in Patients with Advanced Lung Adenocarcinoma.
Kashima J; Okuma Y; Hosomi Y; Hishima T
Oncology; 2020; 98(5):303-310. PubMed ID: 32097938
[TBL] [Abstract][Full Text] [Related]
6. Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.
Chen P; Zhang L; Zhang W; Sun C; Wu C; He Y; Zhou C
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082168
[TBL] [Abstract][Full Text] [Related]
7. OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer.
Deng J; Zhao S; Zhang X; Jia K; Wang H; Zhou C; He Y
Onco Targets Ther; 2019; 12():7347-7353. PubMed ID: 31564917
[TBL] [Abstract][Full Text] [Related]
8. Spatial Mapping and Immunomodulatory Role of the OX40/OX40L Pathway in Human Non-Small Cell Lung Cancer.
Porciuncula A; Morgado M; Gupta R; Syrigos K; Meehan R; Zacharek SJ; Frederick JP; Schalper KA
Clin Cancer Res; 2021 Nov; 27(22):6174-6183. PubMed ID: 34518312
[TBL] [Abstract][Full Text] [Related]
9. OX40 and OX40L Interaction in Cancer.
Lu X
Curr Med Chem; 2021; 28(28):5659-5673. PubMed ID: 33372866
[TBL] [Abstract][Full Text] [Related]
10. Multiple levels of activation of murine CD8(+) intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-gamma, and IL-10 regulation.
Wang HC; Klein JR
J Immunol; 2001 Dec; 167(12):6717-23. PubMed ID: 11739485
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of OX40
Yokouchi H; Nishihara H; Harada T; Amano T; Ohkuri T; Yamazaki S; Kikuchi H; Oizumi S; Uramoto H; Tanaka F; Harada M; Akie K; Sugaya F; Fujita Y; Takamura K; Kojima T; Higuchi M; Honjo O; Minami Y; Watanabe N; Nishimura M; Suzuki H; Dosaka-Akita H; Isobe H
Oncoimmunology; 2021; 10(1):1971430. PubMed ID: 34552823
[TBL] [Abstract][Full Text] [Related]
12. OX40/OX40 ligand and its role in precision immune oncology.
Thapa B; Kato S; Nishizaki D; Miyashita H; Lee S; Nesline MK; Previs RA; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Metastasis Rev; 2024 Mar; ():. PubMed ID: 38526805
[TBL] [Abstract][Full Text] [Related]
13. In Situ Reprogramming of Tumors for Activating the OX40/OX40 Ligand Checkpoint Pathway and Boosting Antitumor Immunity.
Gao Y; Zhao J; Huang Z; Zhao H; Guo Z; Ma S; Tang X; Song W; Chen X
ACS Biomater Sci Eng; 2023 Jul; 9(7):4108-4116. PubMed ID: 35653749
[TBL] [Abstract][Full Text] [Related]
14. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.
Blazar BR; Sharpe AH; Chen AI; Panoskaltsis-Mortari A; Lees C; Akiba H; Yagita H; Killeen N; Taylor PA
Blood; 2003 May; 101(9):3741-8. PubMed ID: 12521997
[TBL] [Abstract][Full Text] [Related]
15. Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.
Chen P; Zhao L; Wang H; Zhang L; Zhang W; Zhu J; Yu J; Zhao S; Li W; Sun C; Wu C; He Y; Zhou C
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362829
[TBL] [Abstract][Full Text] [Related]
16. Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia.
Cui D; Lv Y; Yuan X; Ruan G; Zhang Y; Yan C; Xu D; Lv M; Mao Y; Cao J; Jin J; Xie J
J Immunol Res; 2019; 2019():6804806. PubMed ID: 30944836
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Bioinformatics Analysis Identifies Tumor Microenvironment and Immune-related Genes in Small Cell Lung Cancer.
Song Y; Sun Y; Sun T; Tang R
Comb Chem High Throughput Screen; 2020; 23(5):381-391. PubMed ID: 32264809
[TBL] [Abstract][Full Text] [Related]
18. Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells.
Kondo K; Okuma K; Tanaka R; Zhang LF; Kodama A; Takahashi Y; Yamamoto N; Ansari AA; Tanaka Y
Hum Immunol; 2007 Jul; 68(7):563-71. PubMed ID: 17584577
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis.
Zhou X; Wang X; Gu Y; Chen L; Shen Y; Tian J; Shujun C; Wang M; Duan X; Gao H; Ji X; Fang Q; Zhang X; Xue Q
J Immunol Res; 2022; 2022():4337399. PubMed ID: 35265719
[TBL] [Abstract][Full Text] [Related]
20. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
